Skip to main content
NVDA-1.38%AAPL+0.39%GOOGL-2.28%MSFT-0.70%AMZN-0.68%TSM-0.83%SPCX-3.86%AVGO-1.13%META-0.31%TSLA-2.02%SKHY+7.05%MU-2.75%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.71%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-2.36%0005.HK-0.78%HSBA.L-1.48%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.41%AUDJPY-1.70%CHFJPY-1.62%NZDCAD-1.32%EURJPY-1.26%NZDUSD-1.26%GBPJPY-1.25%EURNZD+1.20%USDJPY-1.18%GBPNZD+1.17%CADJPY-1.10%USDZAR+0.84%NZDCHF-0.82%USDNOK+0.79%AUDNZD+0.74%USDSEK+0.70%AUDCAD-0.62%USDTHB+0.61%EURZAR+0.60%EURNOK+0.54%GBPZAR+0.54%AUDUSD-0.51%CADCHF+0.50%USDPLN+0.49%AUDSGD-0.48%USDMXN+0.48%AUDDKK-0.47%EURSEK+0.46%USDCHF+0.46%EURAUD+0.45%GBPAUD+0.42%GBPTRY+0.41%CHFNOK+0.39%EURCHF+0.36%GBPCHF+0.36%GBPHKD+0.32%SGDJPY+0.32%CHFSEK+0.31%NZDSGD-0.29%GBPMXN-0.28%EURHKD-0.26%USDDKK+0.25%USDSGD+0.24%EURPLN+0.24%NOKJPY-0.23%EURCNH-0.17%GBPCAD-0.16%USDILS+0.16%CHFSGD-0.16%EURCAD-0.15%USDTRY+0.11%EURUSD-0.08%GBPSGD-0.07%GBPUSD-0.07%PLNJPY+0.07%AUDCHF-0.07%NZDMXN-0.07%AUDNOK+0.06%USDCAD-0.06%USDCNH+0.06%USDCOP-0.04%EURCZK-0.02%EURGBP+0.02%EURSGD-0.01%USDHKD0.00%EURDKK0.00%GAGUSD-4.64%XAGUSD-4.64%XPTUSD-4.57%HG1-4.04%USOIL+3.43%UKOIL+3.26%COFFEE-2.23%XAUUSD-1.35%GAUUSD-1.34%SUGAR+0.65%XNGUSD-0.57%COTTON+0.32%BTCUSD-1.62%ETHUSD-1.43%USDTUSD-0.03%XRPUSD-2.04%SOLUSD-1.76%TRXUSDT+0.12%ZECUSDT-2.70%DOGEUSD-1.89%XMRUSDT-1.95%LINKUSD-1.00%XLMUSD-1.69%BCHUSDT-4.03%LTCUSD-2.05%UNIUSD-3.20%TONUSD+24.88%HBARUSDT-2.15%SUIUSD-2.13%TAOUSDT-3.31%AAVEUSD-2.63%DOTUSDT-2.36%ICPUSDT-1.44%ONDOUSDT-2.70%WLDUSDT-1.71%ATOMUSDT-2.97%ARBUSDT-0.78%JUPUSDT-3.39%INJUSDT-3.40%STXUSDT-3.80%FETUSDT-3.12%TIAUSDT-1.13%PYTHUSDT-1.61%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-3.91%GRTUSDT-4.03%OPUSDT-1.99%POLUSDT-6.46%IOTAUSDT-4.02%AXSUSDT-2.57%FARTCOINUSDT-4.23%EOSUSDT-0.31%DYDXUSDT-0.53%ORDIUSDT-0.40%GALAUSDT-4.21%NOTUSDT-0.68%RONINUSDT-1.67%NVDA-1.38%AAPL+0.39%GOOGL-2.28%MSFT-0.70%AMZN-0.68%TSM-0.83%SPCX-3.86%AVGO-1.13%META-0.31%TSLA-2.02%SKHY+7.05%MU-2.75%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.71%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-2.36%0005.HK-0.78%HSBA.L-1.48%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.41%AUDJPY-1.70%CHFJPY-1.62%NZDCAD-1.32%EURJPY-1.26%NZDUSD-1.26%GBPJPY-1.25%EURNZD+1.20%USDJPY-1.18%GBPNZD+1.17%CADJPY-1.10%USDZAR+0.84%NZDCHF-0.82%USDNOK+0.79%AUDNZD+0.74%USDSEK+0.70%AUDCAD-0.62%USDTHB+0.61%EURZAR+0.60%EURNOK+0.54%GBPZAR+0.54%AUDUSD-0.51%CADCHF+0.50%USDPLN+0.49%AUDSGD-0.48%USDMXN+0.48%AUDDKK-0.47%EURSEK+0.46%USDCHF+0.46%EURAUD+0.45%GBPAUD+0.42%GBPTRY+0.41%CHFNOK+0.39%EURCHF+0.36%GBPCHF+0.36%GBPHKD+0.32%SGDJPY+0.32%CHFSEK+0.31%NZDSGD-0.29%GBPMXN-0.28%EURHKD-0.26%USDDKK+0.25%USDSGD+0.24%EURPLN+0.24%NOKJPY-0.23%EURCNH-0.17%GBPCAD-0.16%USDILS+0.16%CHFSGD-0.16%EURCAD-0.15%USDTRY+0.11%EURUSD-0.08%GBPSGD-0.07%GBPUSD-0.07%PLNJPY+0.07%AUDCHF-0.07%NZDMXN-0.07%AUDNOK+0.06%USDCAD-0.06%USDCNH+0.06%USDCOP-0.04%EURCZK-0.02%EURGBP+0.02%EURSGD-0.01%USDHKD0.00%EURDKK0.00%GAGUSD-4.64%XAGUSD-4.64%XPTUSD-4.57%HG1-4.04%USOIL+3.43%UKOIL+3.26%COFFEE-2.23%XAUUSD-1.35%GAUUSD-1.34%SUGAR+0.65%XNGUSD-0.57%COTTON+0.32%BTCUSD-1.62%ETHUSD-1.43%USDTUSD-0.03%XRPUSD-2.04%SOLUSD-1.76%TRXUSDT+0.12%ZECUSDT-2.70%DOGEUSD-1.89%XMRUSDT-1.95%LINKUSD-1.00%XLMUSD-1.69%BCHUSDT-4.03%LTCUSD-2.05%UNIUSD-3.20%TONUSD+24.88%HBARUSDT-2.15%SUIUSD-2.13%TAOUSDT-3.31%AAVEUSD-2.63%DOTUSDT-2.36%ICPUSDT-1.44%ONDOUSDT-2.70%WLDUSDT-1.71%ATOMUSDT-2.97%ARBUSDT-0.78%JUPUSDT-3.39%INJUSDT-3.40%STXUSDT-3.80%FETUSDT-3.12%TIAUSDT-1.13%PYTHUSDT-1.61%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-3.91%GRTUSDT-4.03%OPUSDT-1.99%POLUSDT-6.46%IOTAUSDT-4.02%AXSUSDT-2.57%FARTCOINUSDT-4.23%EOSUSDT-0.31%DYDXUSDT-0.53%ORDIUSDT-0.40%GALAUSDT-4.21%NOTUSDT-0.68%RONINUSDT-1.67%
PB

Pacira BioSciences, Inc. (PCRX)

NASDAQ • Healthcare

$25.88
+$0 (+0.0%)
Market closed

Last close at September 9, 2026 at 20:00 UTC

Open$25.62
Day Range$25.13 - $25.88
Avg. Volume (3M)520K
Market Cap$1B
P/E Ratio73.9
52 Week Range
$18.8$27.66
Next EarningsIn 56 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$192.3M100%
Gross Profitminus cost of goods$148.2M77%
Operating Incomeminus R&D and overhead$4.2M2%
Net Incomeminus taxes and the rest$4.6M2%

In plain terms: out of every $100 in revenue, Pacira BioSciences, Inc. keeps $2 as net profit.

Fundamentals & Financials

Revenue (TTM)
$746.1M
Net Income (TTM)
$14.6M
EPS (TTM)
$0.35
ROA (TTM)
1.18%
Current Ratio
5.04

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-32.9%Q1 2026$0.57
-1.6%Q2 2026$0.6
+13.0%Q3 2026$0.73
Next

Nov 5

in 56 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +13.0%

Pacira BioSciences beat expectations on adjusted EPS while revenue came in line with consensus, as its second fiscal quarter of 2026 results reported August 4, 2026 showed revenue up 6.2% year over year to roughly $192.4 million. On the bottom line, adjusted EPS of $0.73 topped the $0.65 estimate (+13%), while revenue of $192.4 million was in line with the $191.1 million estimate (+0.7%). Profitability remained high on a gross basis, with gross profit of about $148.2 million translating to a gross margin near 77%, and operating income of roughly $4.3 million for an operating margin around 2.2%. Net income was about $4.7 million, a swing from net income of -$4.8 million a year ago. The quarter also generated operating cash flow of about $57.5 million. For the next period, consensus calls for EPS of $0.76 on revenue of $181.8 million.

View full earnings history

About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. develops and sells non-opioid pain-management and regenerative-health products in the healthcare sector. Listed on NASDAQ as PCRX, the company markets prescription therapies and a medical device in the United States, generating $726.4 million of revenue in FY2025.

Name
Pacira BioSciences, Inc.
CEO
Frank D. Lee
Website
www.pacira.com
Industry
Healthcare
Year Founded
2006
Employees
827

Today's Snapshot

AI-generated

PCRX closed flat at 25.88.

Trading Volume

Above 10d avg 516.2K

529.2K

vs S&P 500 Today

Outperforming Market

+0.52%

Updated: September 10, 2026 at 12:27 UTC

Technical Indicators

5 Buy2 Neutral1 Sell
PCRX trades near $25.88 and registers a modest bullish bias as several trend and momentum measures align. The MACD and short momentum readings favor buyers while the RSI and stochastics are middling, and the stock sits just below very short-term averages yet above its 20–200-day moving averages, which supports broader upside. ADX indicates only a developing trend and ATR shows moderate volatility, while on-balance volume is constructive. Technical takeaway: Buy — broader moving average structure and positive momentum indicators tilt the setup toward buyers despite limited trend strength.
All signals
  • EMA (5 indicators)$24.26 - $25.92
    Buy
  • RSI (14)54.21
    Neutral
  • Stochastic %K (14, 3, 3)73.57
    Neutral
  • MACD Level (12, 26)0.33
    Buy

Peers & Related Assets

URGNUroGen Pharma Ltd.
$45+2.7%
KODKodiak Sciences Inc.
$33.78-3.7%
XNCRXencor, Inc.
$24.94-1.5%
ANABAnaptysBio, Inc.
$55.7-1.6%
TNDMTandem Diabetes Care, Inc.
$19.11-3.9%
CRONCronos Group Inc.
$3.16-1.1%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.